For instance, combining CTLA‐4 inhibitors with PD‐1/PD‐L1 antibodies can activate the INF‐γ pathway and other pathways, potentially inducing the upregulation of additional immune checkpoints on tumor‐infiltrating lymphocytes, ultimately resulting in treatment failure. Here, PDCD1 is linked to neoplasm.